Why is Genomic Health reporting out quantitative HER2 scores?
Many clinicians who rely on Recurrence Score results for treatment planning have requested that Genomic Health also report a quantitative HER2 Score as a means to complement current testing and potentially provide further clarification of conflicting or ambiguous results. The Recurrence Score result remains the best tool for assessing prognosis and prediction of chemotherapy benefit.
